Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOGEN INC.BIIB · Entity 1675 | Director | December 31, 2020 | February 09, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOGEN INC.
Report date December 31, 2020 · Filed February 09, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectRobin Drive, LLC | 16,000 |
Reported balance
After 2020-12-31 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2020-12-31 · Gift · Acquired 16,000 · Balance 16,000 F1: Reporting person gifted shares to the Robin Drive, LLC (the "Trust"), of which his wife is Trustee, on December 31, 2020. Reporting person disclaims all beneficial ownership of the shares held by the Trust. |
| Common StockSEC Table I · non-derivative | Direct | 4,632 |
Reported balance
After 2020-12-31 transaction · row 2
1 source rowRow 2 · 2020-12-31 · Gift · Disposed 16,000 · Balance 4,632 F1: Reporting person gifted shares to the Robin Drive, LLC (the "Trust"), of which his wife is Trustee, on December 31, 2020. Reporting person disclaims all beneficial ownership of the shares held by the Trust. |
Filing footnotes · ownership attribution and instrument terms
F1: Reporting person gifted shares to the Robin Drive, LLC (the "Trust"), of which his wife is Trustee, on December 31, 2020. Reporting person disclaims all beneficial ownership of the shares held by the Trust.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 31, 2020 Filed Feb 9, 2021 21:14 UTC | BIOGEN INC. BIIB · Entity 1675 | GiftCommon Stock | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-004675 · form5.xml · nonDerivative · entry 2 PANGIA ROBERT W · CIK 0001236188 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,632 F1 · kind: Reporting person gifted shares to the Robin Drive, LLC (the "Trust"), of which his wife is Trustee, on December 31, 2020. Reporting person disclaims all beneficial ownership of the shares held by the Trust. Read SEC document |
| December 31, 2020 Filed Feb 9, 2021 21:14 UTC | BIOGEN INC. BIIB · Entity 1675 | GiftCommon Stock | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-004675 · form5.xml · nonDerivative · entry 1 PANGIA ROBERT W · CIK 0001236188 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Robin Drive, LLC Disclosed balance after: 16,000 F1 · kind: Reporting person gifted shares to the Robin Drive, LLC (the "Trust"), of which his wife is Trustee, on December 31, 2020. Reporting person disclaims all beneficial ownership of the shares held by the Trust. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 21:19 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 890 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-019029 · form4.xml · nonDerivative · entry 1 PANGIA ROBERT W · CIK 0001236188 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,632 Read SEC document |
| June 19, 2019 Filed Jun 20, 2019 21:52 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 1,155 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-022422 · form4.xml · nonDerivative · entry 1 PANGIA ROBERT W · CIK 0001236188 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,742 Read SEC document |
| March 18, 2019 Filed Mar 19, 2019 20:08 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,114 | Not disclosed Strike: $53.43 | Not disclosed |
DisclosureSEC source: 0001127602-19-012198 · form4.xml · derivative · entry 3 PANGIA ROBERT W · CIK 0001236188 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,114 shares Expires 2019-06-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: This option was previously reported as covering 5,975 shares at an exercise price of $53.43 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F3 · derivative.exercise_price: Granted under one of the Issuer's stock option plans, in an exempt transaction under SEC Rule 16(b)-3(d). F1 · kind: Exercise/sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. F2 · shares: This option was previously reported as covering 5,975 shares at an exercise price of $53.43 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F2 · price: This option was previously reported as covering 5,975 shares at an exercise price of $53.43 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F2 · derivative.underlying_shares: This option was previously reported as covering 5,975 shares at an exercise price of $53.43 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. Read SEC document |
| March 18, 2019 Filed Mar 19, 2019 20:08 UTC | BIOGEN INC. BIIB · Entity 1675 | SaleCommon Stock | 6,114 | $328.55 | $2,008,754.70 |
DisclosureSEC source: 0001127602-19-012198 · form4.xml · nonDerivative · entry 2 PANGIA ROBERT W · CIK 0001236188 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,587 F1 · kind: Exercise/sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| March 18, 2019 Filed Mar 19, 2019 20:08 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 6,114 | $52.22 | $319,273.08 |
DisclosureSEC source: 0001127602-19-012198 · form4.xml · nonDerivative · entry 1 PANGIA ROBERT W · CIK 0001236188 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,701 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise/sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. F2 · shares: This option was previously reported as covering 5,975 shares at an exercise price of $53.43 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F2 · price: This option was previously reported as covering 5,975 shares at an exercise price of $53.43 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 21:33 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 880 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-020966 · form4.xml · nonDerivative · entry 1 PANGIA ROBERT W · CIK 0001236188 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,587 Read SEC document |
| January 09, 2018 Filed Jan 10, 2018 22:28 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,832 | $0.00 Strike: $57.83 | $0.00 |
DisclosureSEC source: 0001127602-18-001563 · form4.xml · derivative · entry 3 PANGIA ROBERT W · CIK 0001236188 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,832 shares Expires 2018-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: This option was previously reported as covering 5,700 shares at an exercise price of $59.17 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F1 · kind: Exercise/sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. F2 · shares: This option was previously reported as covering 5,700 shares at an exercise price of $59.17 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F2 · derivative.underlying_shares: This option was previously reported as covering 5,700 shares at an exercise price of $59.17 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. Read SEC document |
| January 09, 2018 Filed Jan 10, 2018 22:28 UTC | BIOGEN INC. BIIB · Entity 1675 | SaleCommon Stock | 5,832 | $329.65 | $1,922,518.80 |
DisclosureSEC source: 0001127602-18-001563 · form4.xml · nonDerivative · entry 2 PANGIA ROBERT W · CIK 0001236188 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,707 F1 · kind: Exercise/sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| January 09, 2018 Filed Jan 10, 2018 22:28 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 5,832 | $57.83 | $337,264.56 |
DisclosureSEC source: 0001127602-18-001563 · form4.xml · nonDerivative · entry 1 PANGIA ROBERT W · CIK 0001236188 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,539 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise/sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| June 07, 2017 Filed Jun 9, 2017 21:50 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 1,055 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-021098 · form4.xml · nonDerivative · entry 1 PANGIA ROBERT W · CIK 0001236188 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,707 F1 · balance_after: On 6/8/16 an RSU was awarded for 1,060 shares. This award was adjusted to 1,084 shares pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. Read SEC document |
| January 09, 2017 Filed Jan 10, 2017 21:15 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,450 | $0.00 Strike: $52.22 | $0.00 |
DisclosureSEC source: 0001127602-17-001434 · form4.xml · derivative · entry 3 PANGIA ROBERT W · CIK 0001236188 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,450 shares Expires 2017-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise/sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. F2 · derivative.exercise_date: Options will become 100% exercisable upon completion of one year of service with Biogen Idec Inc. Read SEC document |
| January 09, 2017 Filed Jan 10, 2017 21:15 UTC | BIOGEN INC. BIIB · Entity 1675 | SaleCommon Stock | 5,450 | $295.39 | $1,609,875.50 |
DisclosureSEC source: 0001127602-17-001434 · form4.xml · nonDerivative · entry 2 PANGIA ROBERT W · CIK 0001236188 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,628 F1 · kind: Exercise/sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| January 09, 2017 Filed Jan 10, 2017 21:15 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 5,450 | $52.22 | $284,599.00 |
DisclosureSEC source: 0001127602-17-001434 · form4.xml · nonDerivative · entry 1 PANGIA ROBERT W · CIK 0001236188 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,078 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise/sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.